Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jan Tack & Maura Corsetti. (2002) Tegaserod: a new 5-HT4 agonist in the treatment of irritable bowel syndrome. Expert Opinion on Pharmacotherapy 3:8, pages 1211-1218.
Read now
Read now
Ashkan Farhadi, Keith Bruninga, Jeremy Fields & Ali Keshavarzian. (2001) Irritable bowel syndrome: an update on therapeutic modalities. Expert Opinion on Investigational Drugs 10:7, pages 1211-1222.
Read now
Read now
Articles from other publishers (35)
Valentina Noemi Madia, Antonella Messore, Francesco Saccoliti, Valeria Tudino, Alessandro De Leo, Daniela De Vita, Martina Bortolami, Luigi Scipione, Ivano Pindinello, Roberta Costi & Roberto Di Santo. (2020) Tegaserod for the Treatment of Irritable Bowel Syndrome. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 19:4, pages 342-369.
Crossref
Crossref
Alexander C Ford, Paul Moayyedi, Brian E Lacy, Anthony J Lembo, Yuri A Saito, Lawrence R Schiller, Edy E Soffer, Brennan M R Spiegel & Eamonn M M Quigley. (2014) American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. American Journal of Gastroenterology 109, pages S2-S26.
Crossref
Crossref
M. Schmulson & L. Chang. (2011) Review article: the treatment of functional abdominal bloating and distension. Alimentary Pharmacology & Therapeutics 33:10, pages 1071-1086.
Crossref
Crossref
Omar M Aboumarzouk, Trisha Agarwal, Ramez Antakia, Umar Shariff & Richard L Nelson. (2011) Cisapride for Intestinal Constipation. Cochrane Database of Systematic Reviews.
Crossref
Crossref
A. C. Ford & P. Moayyedi. (2010) Meta‐analysis: factors affecting placebo response rate in the irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 32:2, pages 144-158.
Crossref
Crossref
Alexander C Ford, Lawrence J Brandt, Christine Young, William D Chey, Amy E Foxx-Orenstein & Paul Moayyedi. (2009) Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. The American Journal of Gastroenterology 104:7, pages 1831-1843.
Crossref
Crossref
Lawrence J. Brandt, William D. Chey, Amy E. Foxx-Orenstein, Eamonn M.M. Quigley, Lawrence R. Schiller, Philip S. Schoenfeld, Brennan M. Spiegel, Nicholas J. Talley & Paul Moayyedi. (2009) An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome. American Journal of Gastroenterology 104, pages S8-S35.
Crossref
Crossref
Mariette Bengtsson, Bodil Ohlsson & Kerstin Ulander. (2007) Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS). BMC Gastroenterology 7:1.
Crossref
Crossref
J. TACK, M. FRIED, L. A. HOUGHTON, J. SPICAK & G. FISHER. (2006) Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Alimentary Pharmacology and Therapeutics 24:2, pages 183-205.
Crossref
Crossref
R. HEADING, K. BARDHAN, S. HOLLERBACH, A. LANAS & G. FISHER. (2006) Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome - a European perspective. Alimentary Pharmacology and Therapeutics 24:2, pages 207-236.
Crossref
Crossref
Jian Ping Liu, Min Yang, Yunxia Liu, Mao Ling Wei & Sameline Grimsgaard. (2006) Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews.
Crossref
Crossref
s. m. patel, w. b. stason, a. legedza, s. m. ock, t. j. kaptchuk, l. conboy, k. canenguez, j. k. park, e. kelly, e. jacobson, c. e. kerr & a. j. lembo. (2005) The placebo effect in irritable bowel syndrome trials: a meta-analysis1. Neurogastroenterology and Motility 17:3, pages 332-340.
Crossref
Crossref
Filippo Cremonini & Nicholas J Talley. (2005) Treatments targeting putative mechanisms in irritable bowel syndrome. Nature Clinical Practice Gastroenterology & Hepatology 2:2, pages 82-88.
Crossref
Crossref
D. Lesbros-Pantoflickova, P. Michetti, M. Fried, C. Beglinger & A. L. Blum. (2004) Meta-analysis: the treatment of irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 20:11-12, pages 1253-1269.
Crossref
Crossref
DIETER J ZIEGENHAGEN & WOLFGANG KRUIS. (2004) Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo. Journal of Gastroenterology and Hepatology 19:7, pages 744-749.
Crossref
Crossref
F. Thielecke, S. Maxion-Bergemann, F. Abel & A-K. Gonschior. (2004) Update in the pharmaceutical therapy of the irritable bowel syndrome. International Journal of Clinical Practice 58:4, pages 374-381.
Crossref
Crossref
Michael D Crowell. (2004) Role of serotonin in the pathophysiology of the irritable bowel syndrome. British Journal of Pharmacology 141:8, pages 1285-1293.
Crossref
Crossref
Yolanda Scarlett. (2004) Medical management of fecal incontinence. Gastroenterology 126, pages S55-S63.
Crossref
Crossref
M. Chovet & L. Buéno. 2003.
89
98
.
Michael J. Callahan. (2002) Irritable Bowel Syndrome Neuropharmacology. Journal of Clinical Gastroenterology 35:Supplement, pages S58-S67.
Crossref
Crossref
Robin Spiller. (2002) Serotonergic modulating drugs for functional gastrointestinal diseases. British Journal of Clinical Pharmacology 54:1, pages 11-20.
Crossref
Crossref
Osama Alaradi & Jamie S. Barkin. (2002) Irritable Bowel Syndrome: Update on Pathogenesis and Management. Medical Principles and Practice 11:1, pages 2-17.
Crossref
Crossref
Dieter J. Ziegenhagen & Wolfgang KruisDieter J. Ziegenhagen & Wolfgang Kruis. 2002. Obstipation und Diarrhö. Obstipation und Diarrhö
47
83
.
Nicholas J Talley. (2001) Serotoninergic neuroenteric modulators. The Lancet 358:9298, pages 2061-2068.
Crossref
Crossref
M. Camilleri. (2008) Tegaserod. Alimentary Pharmacology & Therapeutics 15:3, pages 277-289.
Crossref
Crossref
Anne M. Rentz, Carmelina Battista, Elyse Trudeau, Robert Jones, Patricia Robinson, Sheldon Sloan, Sonika Mathur, Lori Frank & Dennis A. Revicki. (2001) Symptom and Health-Related Quality-of-Life Measures for Use in Selected Gastrointestinal Disease Studies. PharmacoEconomics 19:4, pages 349-363.
Crossref
Crossref
Rebecca C. Dunphy & G. Nicholas Verne. (2001) Drug Treatment Options for Irritable Bowel Syndrome. Drugs & Aging 18:3, pages 201-211.
Crossref
Crossref
Augusto Villanueva, J. Enrique Domínguez-Muñoz & Fermín Mearin. (2001) Update in the Therapeutic Management of Irritable Bowel Syndrome. Digestive Diseases 19:3, pages 244-250.
Crossref
Crossref
John E. Pandolfino, Colin W. Howden & Peter J. Kahrilas. (2000) Motility-modifying agents and management of disorders of gastrointestinal motility. Gastroenterology 118:2, pages S32-S47.
Crossref
Crossref
Jeffrey L Jackson, Patrick G O’Malley, Glen Tomkins, Erin Balden, James Santoro & Kurt Kroenke. (2000) Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis11The opinions in this article represent those of the authors and are not to be construed, in any way, to represent those of the U.S. Army or the Department of Defense.. The American Journal of Medicine 108:1, pages 65-72.
Crossref
Crossref
NICHOLAS J. TALLEY & NATASHA KOLOSKI. 2000. Women and Health. Women and Health
1098
1109
.
S C. Yuan, F J. Foss, M O'Connor, J Osinski, F M. Roizen & J Moss. (1999) Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study ☆. Pain 83:3, pages 631-635.
Crossref
Crossref
Uri Ladabaum & William L. Hasler. (1999) Motility of the small intestine. Current Opinion in Gastroenterology 15:2, pages 125.
Crossref
Crossref
Scott M. Browning. (1999) CONSTIPATION, DIARRHEA, AND IRRITABLE BOWEL SYNDROME. Primary Care: Clinics in Office Practice 26:1, pages 113-139.
Crossref
Crossref
Max J. Schmulson & Emeran A. Mayer. (1999) Evolving concepts in irritable bowel syndrome. Current Opinion in Gastroenterology 15:1, pages 16.
Crossref
Crossref